Gland Pharma Secures FDA Nod for Eye Allergy OTC Drug

• Gland Pharma received FDA approval for its olopatadine hydrochloride ophthalmic solution USP, 0.7% (OTC).
• The drug is indicated for ocular itching associated with allergic conjunctivitis, offering an over-the-counter option.
• It is therapeutically equivalent to Pataday Once Daily Relief 0.7% by Alcon Laboratories Inc.
• This approval strengthens Gland Pharma's ophthalmic segment and expands its presence in the US market.
• Gland Pharma's shares closed up 0.99% on the NSE following the announcement.

Why It Matters: Gland Pharma's FDA approval for its eye allergy drug enhances its market position and provides a new OTC treatment.